Tiziana Life Sciences Ltd (TLSA) FinancialsTLSATiziana Life Sciences Ltd

Evaluating the bottom line, Tiziana Life Sciences Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -232.31%, provide a clear picture of how effectively TLSA converts its operational activities into shareholder value.

In the context of the broader market, TLSA competes directly with industry leaders such as VTVT and CPIX. With a market capitalization of $137.44M, it holds a leading position in the sector. When comparing efficiency, TLSA's gross margin of N/A stands against VTVT's N/A and CPIX's 100.00%. Such benchmarking helps identify whether Tiziana Life Sciences Ltd is trading at a premium or discount relative to its financial performance.

Tiziana Life Sciences has a negative P/E ratio of -4.39 and a price-to-sales ratio of -38.23, indicating financial challenges. However, the recent updates on therapy data suggest potential for future growth.